TGTX Tg Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TGTX
Price (delayed)
$33.1
Market cap
$5.25B
P/E Ratio
80.73
Dividend/share
N/A
EPS
$0.41
Enterprise value
$5.37B
Relative Growth:
Rel. Growth:
81
Relative Strength:
Rel. Strength:
66
Relative Valuation:
Rel. Valuation:
12
Relative Profitability:
Rel. Profitability:
84
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active
Highlights
The equity has surged by 56% year-on-year and by 16% since the previous quarter
The revenue rose by 31% YoY and by 18% QoQ
The company's net income has surged by 54% QoQ but it fell by 37% YoY
Tg Therapeutics's EPS has surged by 52% QoQ but it has decreased by 40% YoY
TGTX's debt has soared by 127% YoY
The gross margin has decreased by 6% YoY
Key stats
What are the main financial stats of TGTX
Market
Valuations
Earnings
Shares outstanding
158.67M
Market cap
$5.25B
Enterprise value
$5.37B
Price to earnings (P/E)
80.73
Price to book (P/B)
19.01
Price to sales (P/S)
10.7
PEG
N/A
EV/EBIT
55.13
EV/EBITDA
55.11
EV/Sales
11.84
Revenue
$454.07M
Gross profit
$394.85M
Operating income
$85.85M
Net income
$60.46M
EBIT
$97.48M
EBITDA
$97.52M
Free cash flow
-$59.24M
Per share
Balance sheet
Liquidity
EPS
$0.41
EPS diluted
$0.37
Free cash flow per share
-$0.4
Book value per share
$1.74
Revenue per share
$3.09
TBVPS
$4.79
Total assets
$702.61M
Total liabilities
$426.18M
Debt
$252.63M
Equity
$276.43M
Working capital
$492.07M
Debt to equity
0.91
Current ratio
3.86
Quick ratio
2.82
Net debt/EBITDA
1.25
Margins
Efficiency
Dividend
EBITDA margin
21.5%
Gross margin
87%
Net margin
13.3%
Operating margin
18.9%
Return on assets
9.6%
Return on equity
26.1%
Return on invested capital
16.6%
Return on capital employed
18.4%
Return on sales
21.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TGTX stock price
How has the Tg Therapeutics stock price performed over time
Intraday
-2.76%
1 week
-2.7%
1 month
-9.96%
1 year
21.83%
YTD
9.97%
QTD
-8.37%
Financial performance
How have Tg Therapeutics's revenue and profit performed over time
Revenue
$454.07M
Gross profit
$394.85M
Operating income
$85.85M
Net income
$60.46M
Gross margin
87%
Net margin
13.3%
The company's net income has surged by 54% QoQ but it fell by 37% YoY
TGTX's net margin has shrunk by 52% YoY but it is up by 32% QoQ
The operating income has grown by 44% from the previous quarter but it has contracted by 16% YoY
Tg Therapeutics's operating margin has decreased by 36% YoY but it has increased by 22% QoQ
Price vs fundamentals
How does TGTX's price correlate with its fundamentals
Growth
What is Tg Therapeutics's growth rate over time
Valuation
What is Tg Therapeutics stock price valuation
P/E
80.73
P/B
19.01
P/S
10.7
EV/EBIT
55.13
EV/EBITDA
55.11
EV/Sales
11.84
Tg Therapeutics's EPS has surged by 52% QoQ but it has decreased by 40% YoY
The equity has surged by 56% year-on-year and by 16% since the previous quarter
The P/B is 14% below the 5-year quarterly average of 22.8 and 10% below the last 4 quarters average of 21.7
The P/S is 100% below the 5-year quarterly average of 2707.0 and 17% below the last 4 quarters average of 13.2
The revenue rose by 31% YoY and by 18% QoQ
Efficiency
How efficient is Tg Therapeutics business performance
The ROA has plunged by 64% YoY but it has grown by 37% from the previous quarter
TGTX's ROIC has shrunk by 56% YoY but it is up by 19% QoQ
The company's return on equity has shrunk by 55% YoY but it rose by 38% QoQ
Tg Therapeutics's return on sales has decreased by 31% YoY but it has increased by 18% QoQ
Dividends
What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TGTX.
Financial health
How did Tg Therapeutics financials performed over time
The total assets is 65% higher than the total liabilities
Tg Therapeutics's total liabilities has surged by 91% YoY
The total assets has soared by 75% YoY and by 7% QoQ
TGTX's debt is 9% lower than its equity
TGTX's debt has soared by 127% YoY
The equity has surged by 56% year-on-year and by 16% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.